NCT02772588View on ClinicalTrials.gov

AASUR in High Risk Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

ARN-509

DRUG

Abiraterone

DRUG

Leuprolide

RADIATION

stereotactic, ultra-fractionated radiotherapy

Trial Locations (11)

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medical Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

19107

Thomas Jefferson University Hospital, Philadelphia

21287

John Hopkins Medical Center, Baltimore

48109

University of Michigan Health System, Ann Arbor

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Unknown

Memorial Sloan Kettering Rockville, Rockville Centre

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

University of Michigan

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02772588 - AASUR in High Risk Prostate Cancer | Biotech Hunter | Biotech Hunter